
PARP Inhibitors Show Promising Response and Clinical Benefit in BRCA-Altered Uterine Leiomyosarcoma
Patients with BRCA-altered uterine leiomyosarcoma (LMS) treated with PARP inhibitors demonstrated encouraging outcomes, including an overall response rate (ORR) of 46%, a clinical benefit rate (CBR) of 62%, and a median progression-free survival (PFS) of …